Indications
Ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA)
Composition
- Active substance
- pitolisant
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ozawade
- Active substance
- pitolisant
- ATC code
- N07XX11
- Group
- Nervous system
- Therapeutic area
- Sleep Apnea, Obstructive
- Marketing authorisation holder
- Bioprojet Pharma
- Status
- Authorised
- EU authorisation
- 1 Sept 2021
- EMA product number